Analystreport

Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.

Paratek Pharmaceuticals, Inc.  (PRTK) 
Last paratek pharmaceuticals, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.paratekpharma.com